Premenstrual Dysphoric Disorder

Teresa Lanza di Scalea; Teri Pearlstein

doi:10.1016/j.mcna.2019.02.007

Premenstrual Dysphoric Disorder

Med Clin North Am. 2019 Jul;103(4):613-628. doi: 10.1016/j.mcna.2019.02.007.

Authors

Teresa Lanza di Scalea¹, Teri Pearlstein²

Affiliations

¹ Assistant Professor of Psychiatry and Women's Health, Dell Medical School, University of Texas at Austin, Austin, TX, USA. Electronic address: teresa.lanza@austin.utexas.edu.
² Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Women's Behavioral Medicine, Women's Medicine Collaborative, Miriam Hospital, 146 West River Street, Providence, RI 02904, USA.

PMID: 31078196
DOI: 10.1016/j.mcna.2019.02.007

Abstract

Premenstrual dysphoric disorder (PMDD) comprises emotional and physical symptoms and functional impairment that lie on the severe end of the continuum of premenstrual symptoms. Women with PMDD have a differential response to normal hormonal fluctuations. This susceptibility may involve the serotonin system, altered sensitivity of the GABA_A receptor to the neurosteroid allopregnanalone, and altered brain circuitry involving emotional and cognitive functions. Serotonin reuptake inhibitors are considered the first-line treatment. Second-line treatments include oral contraceptives containing drospirenone, other ovulation suppression methods, calcium, chasteberry, and cognitive-behavioral therapy.

Keywords: Antidepressant; Etiology; Oral contraceptive; Premenstrual dysphoric disorder; Premenstrual syndrome; Treatment.

Publication types

Review

MeSH terms

Contraceptives, Oral / therapeutic use
Contraceptives, Oral, Hormonal / therapeutic use*
Female
Humans
Premenstrual Dysphoric Disorder / diagnosis*
Premenstrual Dysphoric Disorder / drug therapy*
Premenstrual Syndrome / diagnosis
Premenstrual Syndrome / drug therapy
Selective Serotonin Reuptake Inhibitors / therapeutic use*
Women's Health

Substances

Contraceptives, Oral
Contraceptives, Oral, Hormonal
Serotonin Uptake Inhibitors